623 related articles for article (PubMed ID: 33787832)
41. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
42. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
43. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
Klein AA; Seppala MD
J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
[TBL] [Abstract][Full Text] [Related]
44. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
45. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
Larochelle MR; Wakeman SE; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
Med Care; 2020 Oct; 58(10):919-926. PubMed ID: 32842044
[TBL] [Abstract][Full Text] [Related]
46. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
47. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Kelty E; Hulse G
Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
[TBL] [Abstract][Full Text] [Related]
48. Reducing overdose deaths among persons with opioid use disorder in connecticut.
Scheidell JD; Townsend TN; Zhou Q; Manandhar-Sasaki P; Rodriguez-Santana R; Jenkins M; Buchelli M; Charles DL; Frechette JM; Su JI; Braithwaite RS
Harm Reduct J; 2024 May; 21(1):103. PubMed ID: 38807226
[TBL] [Abstract][Full Text] [Related]
49. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
52. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
[TBL] [Abstract][Full Text] [Related]
53. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
[TBL] [Abstract][Full Text] [Related]
54. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
55. Court personnel attitudes towards medication-assisted treatment: A state-wide survey.
Andraka-Christou B; Gabriel M; Madeira J; Silverman RD
J Subst Abuse Treat; 2019 Sep; 104():72-82. PubMed ID: 31370988
[TBL] [Abstract][Full Text] [Related]
56. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
[TBL] [Abstract][Full Text] [Related]
57. A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder.
Gottlieb DJ; Shiner B; Hoyt JE; Riblet NB; Peltzman T; Teja N; Watts BV
Acta Psychiatr Scand; 2023 Jan; 147(1):6-15. PubMed ID: 35837885
[TBL] [Abstract][Full Text] [Related]
58. Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event.
Alexander M; Hooker J; Stratton M; Huh M; Houck K
J Am Pharm Assoc (2003); 2024; 64(3):101999. PubMed ID: 38151200
[TBL] [Abstract][Full Text] [Related]
59. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
60. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
